Pharmaceutical Methods
Publishing Quality Research & Reviews
Author(s): Sabyasachi Biswal1, Sumanta Mondal1*, Prasenjit Mondal2
The present research work described about the systemic development of High-Performance Liquid Chromatography (HPLC) method for the quantitative determination of ruxolitinib in bulk and tablet dosage form. The subsequent validation and degradation study was also performed. Methods: The chromatographic Separation was achieved with a HPLC (Waters-717 series) Symmetry ODS RP C18, 250mm x 4.6mm.i.d., 5μm,column with an isocratic mobile phase containing a mixture of acetonitrile: methanol: 1% Ortho phosphoric acid in the volume ratio of 70:25:5. The flow rate of the mobile phase was 1 ml/min and detection wavelength at 258 nm. The developed method was validated according to the ICH guidelines with respect to linearity, accuracy, precision, specificity, detection limits and robustness. Results: The precision of the results, stated as the %RSD was below 1.0%. The accuracy of the method demonstrated at three levels in the range of 50%, 100% and 150% of the specification limit. The calibration curve was linear over a concentration range from 5 to 200μg/ml with a correlation coefficient of 0.9997. The recovery of ruxolitinib was found to be in the range of 98 to 101%, whereas the detection limits were found to be 0.09 and quantitation limit was 0.29 μg/ml. Forced degradation study reveals its higher degradation at thermal and peroxide conditions in compare to other degradation condition. Conclusion: The present method was validated according to the ICH guidelines and it is applied successfully for the determination of ruxolitinib in tablets.
Pharmaceutical Methods received 3403 citations as per google scholar report